Nektar Therapeutics (NKTR)

NASDAQ: NKTR · IEX Real-Time Price · USD
1.745
-0.010 (-0.57%)
May 20, 2024, 9:57 AM EDT - Market open
-0.57%
Market Cap 321.34M
Revenue (ttm) 90.17M
Net Income (ttm) -175.84M
Shares Out 183.63M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 168,598
Open 1.750
Previous Close 1.755
Day's Range 1.740 - 1.770
52-Week Range 0.410 - 1.930
Beta 0.71
Analysts Hold
Price Target 3.50 (+100.0%)
Earnings Date May 9, 2024

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 3, 1994
Employees 137
Stock Exchange NASDAQ
Ticker Symbol NKTR
Full Company Profile

Financial Performance

In 2023, NKTR's revenue was $90.12 million, a decrease of -2.10% compared to the previous year's $92.06 million. Losses were -$276.06 million, -25.03% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for NKTR stock is "Hold." The 12-month stock price forecast is $3.5, which is an increase of 100.00% from the latest price.

Price Target
$3.5
(100.00% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Nektar Therapeutics Reports First Quarter 2024 Financial Results

SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securitie...

10 days ago - PRNewsWire

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based fi...

17 days ago - PRNewsWire

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

TEL AVIV, Israel and SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses AI to transform antibodies into intelligent medicinal solutions, today announc...

26 days ago - GlobeNewsWire

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

SAN FRANCISCO , March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtua...

2 months ago - PRNewsWire

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiatio...

2 months ago - PRNewsWire

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023. Cash and investments in ...

2 months ago - PRNewsWire

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced that it has e...

2 months ago - PRNewsWire

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, Ma...

2 months ago - PRNewsWire

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, a...

2 months ago - PRNewsWire

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

SAN FRANCISCO , Jan. 3, 2024 /PRNewswire/ -- Nektar (Nasdaq: NKTR) management is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Janua...

4 months ago - PRNewsWire

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

– NKTR-255 Combination Expanded NK Cells and Enhanced ADCC Against Rituximab-Resistant Burkitt Lymphoma (BL) Cells – SAN FRANCISCO , Dec. 11, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) ann...

5 months ago - PRNewsWire

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

SAN FRANCISCO , Nov. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2023. Cash and investments in marketable secu...

6 months ago - PRNewsWire

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-ba...

7 months ago - PRNewsWire

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period – – New Data Presented Show ...

7 months ago - PRNewsWire

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

– Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be Presented in Late-Breaking Oral Presentation – SAN FRANCISCO , Oct. 2, 2023 /PRNewswire/ -- Nekt...

8 months ago - PRNewsWire

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

SAN FRANCISCO , Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. ("CBM...

8 months ago - PRNewsWire

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study New Phase 2a Study Also Being Planned for Rezpegaldesleukin in Alopecia Areata ...

8 months ago - PRNewsWire

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

SAN FRANCISCO , Sept. 6, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m.

9 months ago - PRNewsWire

Nektar Therapeutics Reports Second Quarter 2023 Financial Results

SAN FRANCISCO , Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable securiti...

10 months ago - PRNewsWire

Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment

Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.

Other symbols: LLY
10 months ago - Reuters

Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated

Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its...

Other symbols: LLY
10 months ago - Market Watch

Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 SAN FRANCISCO , Aug...

10 months ago - PRNewsWire

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-base...

10 months ago - PRNewsWire

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Glo...

1 year ago - PRNewsWire

Nektar Therapeutics Reports First Quarter 2023 Financial Results

SAN FRANCISCO , May 9, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023. Cash and investments in marketable securitie...

1 year ago - PRNewsWire